2015
Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV
Valcour VG, Spudich SS, Sailasuta N, Phanuphak N, Lerdlum S, Fletcher JL, Kroon ED, Jagodzinski LL, Allen IE, Adams CL, Prueksakaew P, Slike BM, Hellmuth JM, Kim JH, Ananworanich J, . Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV. PLOS ONE 2015, 10: e0142600. PMID: 26555069, PMCID: PMC4640512, DOI: 10.1371/journal.pone.0142600.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyStandard combination antiretroviral therapyLog10 HIV RNAAcute HIVCSF cytokinesHIV RNACentral nervous system outcomesIntegrase inhibitorsGamma-induced protein 10Duration of HIVFiebig stages IAcute HIV infectionHIV RNA levelsCNS outcomesAntiretroviral therapyInflammatory markersWeek 24Antiretroviral treatmentHIV infectionPlasma neopterinRandomized armProspective evaluationMean ageHealthy controlsCCR5 antagonists
2009
Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW. Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection. PLOS ONE 2009, 4: e6877. PMID: 19721718, PMCID: PMC2731205, DOI: 10.1371/journal.pone.0006877.Peer-Reviewed Original ResearchConceptsHIV-1 infectionRaltegravir concentrationsCerebrospinal fluidTreatment-experienced HIV-1-infected patientsSystemic HIV-1 infectionHIV-1-infected patientsHIV-1-infected individualsIntegrase inhibitorsCentral nervous system penetrationAntiretroviral treatment regimensDrug entryPlasma albumin ratioCerebrospinal fluid concentrationsBlood-CSF barrierCSF albumin concentrationPlasma raltegravir concentrationsTreatment regimensAlbumin ratioDrug classesCSF specimensHIV-1CSF samplesAlbumin concentrationFluid concentrationsLiquid chromatography-tandem mass spectrometry